Patents by Inventor Manfred Schudok

Manfred Schudok has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Imino acid derivatives as inhibitors of matrix metalloproteinases
    Publication number: 20050004166
    Abstract: The invention relates to a bicycloazaheterocyclyl carboxylic acid sulfonamide derivative of formula I herein, pharmaceutical preparation comprising it, process for preparing it and method for its pharmaceutical use.
    Type: Application
    Filed: January 5, 2004
    Publication date: January 6, 2005
    Applicant: AVENTIS PHARMA DEUTSCHLAND GMBH
    Inventors: Manfred Schudok, Sven Ruf, Hans Matter, Volkmar Wehner, Reinhard Kirsch, Petra Stahl
  • Cyclic and heterocyclic N-substituted &agr;-iminohydroxamic and -carboxylic acids
    Patent number: 6815440
    Abstract: Cyclic and heterocyclic N-substituted &agr;-iminohydroxamic and -carboxylic acids Compounds of the formula I are suitable for preparing pharmaceuticals for the treatment of disorders in the course of which is involved an increased activity of matrix-degrading metalloproteinases.
    Type: Grant
    Filed: March 3, 2003
    Date of Patent: November 9, 2004
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Werner Thorwart, Wilfried Schwab, Manfred Schudok, Burkhard Haase, Eckart Bartnik, Klaus-Ulrich Weithmann
  • Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
    Patent number: 6743790
    Abstract: The present invention relates to compounds of the formula I, in which R1, R2, R3, R4, R5, R6, A, X, m and n have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of thromboembolic diseases and restenoses. They are reversible inhibitors of the blood clotting enzyme factor VIIa and can in general be applied in conditions in which an undesired activity of factor VIIa is present or for the cure or prevention of which an inhibition of factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, for example as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
    Type: Grant
    Filed: June 6, 2001
    Date of Patent: June 1, 2004
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Otmar Klingler, Manfred Schudok, Hans-Peter Nestler, Hans Matter, Herman Schreuder
  • Urea derivatives with antiproteolytic activity
    Patent number: 6706715
    Abstract: The present invention relates to compounds of the formula I, in which R1, R2, R4, R5, D1, D2, X1, X2, X3, A and B have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of thromboembolic diseases and restenoses. They are reversible inhibitors of the blood clotting enzyme factor VIIa and can in general be applied in conditions in which an undesired activity of factor VIIa is present or for the cure or prevention of which an inhibition of factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
    Type: Grant
    Filed: June 26, 2002
    Date of Patent: March 16, 2004
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Manfred Schudok, Otmar Klingler, Hans-Peter Nestler, Hans Matter, Herman Schreuder, Hauke Szillat
  • Malonamid and malonamic ester derivatives with antithrombotic activity, their preparation, and their use
    Publication number: 20040034027
    Abstract: Compounds of formula I, 1
    Type: Application
    Filed: August 6, 2003
    Publication date: February 19, 2004
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Manfred Schudok, Otmar Klingler, Hans-Peter Nestler, Hans Matter, Herman Schreuder
  • Malonamid and malonamic ester derivatives with antithrombotic activity, their preparation, and their use
    Patent number: 6645992
    Abstract: Compounds of formula I, in which R1, R2, A, and B having the definitions set forth in the claims, are valuable pharmacologically active compounds, which exhibit a strong antithrombotic effect and are suitable, for example, for treating thromboembolic diseases and restenoses. They are reversible inhibitors of the blood clotting enzyme factor VIIa and can in general be applied in conditions in which an undesired activity of factor VIIa is present or for the cure or prevention of which an inhibition of factor VIIa is intended. Also disclosed are processes for the preparation of compounds of formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
    Type: Grant
    Filed: October 1, 2001
    Date of Patent: November 11, 2003
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Manfred Schudok, Otmar Klingler, Hans-Peter Nestler, Hans Matter, Herman Schreuder
  • Urea derivatives with antiproteolytic activity
    Publication number: 20030176439
    Abstract: The present invention relates to compounds of the formula I, 1
    Type: Application
    Filed: June 26, 2002
    Publication date: September 18, 2003
    Applicant: Aventis Pharma Dutschland GmbH
    Inventors: Manfred Schudok, Otmar Klingler, Hans-Peter Nestler, Hans Matter, Herman Schreuder, Hauke Szillat
  • Cyclic and heterocyclic N-substituted alpha-iminohydroxamic and -carboxylic acids
    Publication number: 20030176432
    Abstract: Cyclic and heterocyclic N-substituted &agr;-iminohydroxamic and -carboxylic acids
    Type: Application
    Filed: March 3, 2003
    Publication date: September 18, 2003
    Applicant: Aventis Pharma Deutschland GmbH.
    Inventors: Werner Thorwart, Wilfried Schwab, Manfred Schudok, Burkhard Haase, Eckart Bartnik, Klaus-Ulrich Weithmann
  • Cyclic and heterocyclic N-substituted &agr;-iminohydroxamic and -carboxylic acids
    Patent number: 6573277
    Abstract: Compounds of the formula I are suitable for preparing pharmaceuticals for the treatment of disorders in the course of which is involved an increased activity of matrix-degrading metalloproteinases.
    Type: Grant
    Filed: February 12, 2001
    Date of Patent: June 3, 2003
    Inventors: Werner Thorwart, Wilfried Schwab, Manfred Schudok, Burkhard Haase, Eckart Bartnik, Klaus-Ulrich Weithmann
  • Sulfonylaminocarboxylic acids
    Publication number: 20030087945
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: June 13, 2002
    Publication date: May 8, 2003
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Werner Thorwart, Wilfried Schwab, Manfred Schudok, Burkhard Haase
  • Malonamid and malonamic ester derivatives with antithrombotic activity, their preparation, and their use
    Publication number: 20030027828
    Abstract: Compounds of formula I, 1
    Type: Application
    Filed: October 1, 2001
    Publication date: February 6, 2003
    Inventors: Manfred Schudok, Otmar Klingler, Hans-Peter Nestler, Hans Matter, Herman Schreuder
  • Sulfonylaminophosphinic and sulfonylaminophosphonic acid derivatives, methods for their preparation and use
    Patent number: 6500811
    Abstract: Compounds of the formula I are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading enzymes is involved.
    Type: Grant
    Filed: March 20, 2001
    Date of Patent: December 31, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Manfred Schudok, Wilfried Schwab, Gerhard Zoller, Eckart Bartnik, Frank Büttner, Klaus-Ulrich Weithmann
  • Factor VIIa inhibitors
    Patent number: 6500803
    Abstract: The present invention relates to compounds of formula I, in which R1, R2, R91, R92, R93, R94, R95, R96, R97, r, s, and t have the meanings indicated in the claims. Compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzyme factor VIIa and can in general be applied in conditions in which an undesired activity of factor VIIa is present or for the cure or prevention of conditions in which an inhibition of factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
    Type: Grant
    Filed: June 7, 2000
    Date of Patent: December 31, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Otmar Klingler, Manfred Schudok, Gerhard Zoller, Uwe Heinelt, Elisabeth Defossa, Hans Matter, Pavel Safar
  • Sulfonylaminocarboxylic acids
    Patent number: 6451824
    Abstract: Compounds of formula (I) are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading metalloproteinases is involved.
    Type: Grant
    Filed: May 8, 1998
    Date of Patent: September 17, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Werner Thorwart, Wilfried Schwab, Manfred Schudok, Burkhard Haase
  • Sulfonylaminophosphinic and sulfonylaminophosphonic acid derivatives, methods for their preparation and use
    Publication number: 20020082246
    Abstract: Compounds of the formula I 1
    Type: Application
    Filed: March 20, 2001
    Publication date: June 27, 2002
    Applicant: Aventis Pharma Deutschland GmbH.
    Inventors: Manfred Schudok, Wilfried Schwab, Gerhard Zoller, Eckart Bartnik, Frank Buttner, Klaus-Ulrich Weithmann
  • Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
    Publication number: 20020052417
    Abstract: The present invention relates to compounds of the formula I, 1
    Type: Application
    Filed: June 6, 2001
    Publication date: May 2, 2002
    Inventors: Otmar Klingler, Manfred Schudok, Hans-Peter Nestler, Hans Matter, Herman Schreuder
  • Substituted diaminocarboxylic acids
    Patent number: 6355673
    Abstract: Compounds of formula (I) are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading metalloproteinases is involved
    Type: Grant
    Filed: October 18, 2000
    Date of Patent: March 12, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Werner Thorwart, Wilfried Schwab, Manfred Schudok, Burkhard Haase, Bernhard Neises, Günter Billen
  • N-arylsulfonylamino acid omega-amides
    Patent number: 6335333
    Abstract: Compounds of the formula I: stereoisomeric forms, and physiologically tolerable salts thereof are suitable for the production of pharmaceuticals for the therapy and prophylaxis of disorders involving matrix-degrading metalloproteinases.
    Type: Grant
    Filed: December 28, 2000
    Date of Patent: January 1, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Wilfried Schwab, Werner Thorwart, Manfred Schudok, Burkhard Haase
  • Cyclic and heterocyclic N-substituted alpha-iminohydroxamic and -carboxylic acids
    Publication number: 20010011134
    Abstract: Cyclic and heterocyclic N-substituted &agr;-iminohydroxamic and -carboxylic acids
    Type: Application
    Filed: February 12, 2001
    Publication date: August 2, 2001
    Applicant: Hoechst Aktiengesellschaft
    Inventors: Werner Thorwart, Wilfried Schwab, Manfred Schudok, Burkhard Haase, Eckart Bartnik, Klaus-Ulrich Weithmann
  • Sulfonylaminophosphinic and sulfonylaminophosphinic acid derivatives, methods for their preparation and use
    Patent number: 6235727
    Abstract: Compounds of the formula I are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading enzymes is involved.
    Type: Grant
    Filed: July 15, 1999
    Date of Patent: May 22, 2001
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Manfred Schudok, Wilfried Schwab, Gerhard Zoller, Eckart Bartnik, Frank Büttner, Klaus-Ulrich Weithmann